Literature DB >> 27179108

Prenatal hyperandrogenism induces alterations that affect liver lipid metabolism.

Giselle Adriana Abruzzese1, Maria Florencia Heber2, Silvana Rocio Ferreira2, Leandro Martin Velez2, Roxana Reynoso3, Omar Pedro Pignataro4, Alicia Beatriz Motta2.   

Abstract

Prenatal hyperandrogenism is hypothesized as one of the main factors contributing to the development of polycystic ovary syndrome (PCOS). PCOS patients have high risk of developing fatty liver and steatosis. This study aimed to evaluate the role of prenatal hyperandrogenism in liver lipid metabolism and fatty liver development. Pregnant rats were hyperandrogenized with testosterone. At pubertal age, the prenatally hyperandrogenized (PH) female offspring displayed both ovulatory (PHov) and anovulatory (PHanov) phenotypes that mimic human PCOS features. We evaluated hepatic transferases, liver lipid content, the balance between lipogenesis and fatty acid oxidation pathway, oxidant/antioxidant balance and proinflammatory status. We also evaluated the general metabolic status through growth rate curve, basal glucose and insulin levels, glucose tolerance test, HOMA-IR index and serum lipid profile. Although neither PH group showed signs of liver lipid content, the lipogenesis and fatty oxidation pathways were altered. The PH groups also showed impaired oxidant/antioxidant balance, a decrease in the proinflammatory pathway (measured by prostaglandin E2 and cyclooxygenase-2 levels), decreased glucose tolerance, imbalance of circulating lipids and increased risk of metabolic syndrome. We conclude that prenatal hyperandrogenism generates both PHov and PHanov phenotypes with signs of liver alterations, imbalance in lipid metabolism and increased risk of developing metabolic syndrome. The anovulatory phenotype showed more alterations in liver lipogenesis and a more impaired balance of insulin and glucose metabolism, being more susceptible to the development of steatosis.
© 2016 Society for Endocrinology.

Entities:  

Keywords:  fatty liver; lipid metabolism; polycystic ovary syndrome; prenatal hyperandrogenism

Mesh:

Substances:

Year:  2016        PMID: 27179108     DOI: 10.1530/JOE-15-0471

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  7 in total

1.  Perinatal programming of adolescent nonalcoholic fatty liver disease: A case for gender inequality?

Authors:  Monika Sarkar; Gyorgy Baffy
Journal:  Hepatology       Date:  2017-11-13       Impact factor: 17.425

Review 2.  Androgen excess and metabolic disorders in women with PCOS: beyond the body mass index.

Authors:  R A Condorelli; A E Calogero; M Di Mauro; L M Mongioi'; R Cannarella; G Rosta; S La Vignera
Journal:  J Endocrinol Invest       Date:  2017-09-23       Impact factor: 4.256

3.  Testosterone Levels in Pre-Menopausal Women are Associated With Nonalcoholic Fatty Liver Disease in Midlife.

Authors:  Monika Sarkar; Melissa Wellons; Marcelle I Cedars; Lisa VanWagner; Erica P Gunderson; Veeral Ajmera; Laura Torchen; David Siscovick; J Jeffrey Carr; James G Terry; Mary Rinella; Cora E Lewis; Norah Terrault
Journal:  Am J Gastroenterol       Date:  2017-03-14       Impact factor: 10.864

Review 4.  The Hepatoprotective and Hepatotoxic Roles of Sex and Sex-Related Hormones.

Authors:  Linlin Xu; Yuan Yuan; Zhaodi Che; Xiaozhi Tan; Bin Wu; Cunchuan Wang; Chengfang Xu; Jia Xiao
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

Review 5.  The effects of assisted reproduction technologies on metabolic health and disease†.

Authors:  Maria Florencia Heber; Grażyna Ewa Ptak
Journal:  Biol Reprod       Date:  2021-04-01       Impact factor: 4.285

6.  Dietary α-Linolenic Acid-Rich Flaxseed Oil Exerts Beneficial Effects on Polycystic Ovary Syndrome Through Sex Steroid Hormones-Microbiota-Inflammation Axis in Rats.

Authors:  Ting Wang; Liping Sha; Yiwei Li; Lili Zhu; Zhen Wang; Ke Li; Haixia Lu; Ting Bao; Li Guo; Xiaoxia Zhang; Hao Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-27       Impact factor: 5.555

7.  Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies.

Authors:  Miguel A Sanchez-Garrido; Manuel Tena-Sempere
Journal:  Mol Metab       Date:  2020-02-05       Impact factor: 7.422

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.